menu

Emerging Treatments: Diagnosis and Treatment of Chronic Fibrosing ILD with a Progressive Lung Disease Phenotype

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Emerging Treatments: Diagnosis and Treatment of Chronic Fibrosing ILD with a Progressive Lung Disease Phenotype

close
1.00 credits
1 Hour

CME/CE Broadcast Replay

Emerging Treatments: Diagnosis and Treatment of Chronic Fibrosing ILD with a Progressive Lung Disease Phenotype
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    Chronic Fibrosing ILD with a Progressive Lung Disease Phenotype (PF-ILD) occurs in multiple, overlapping clinical settings, and differentiating them can be frustrating and fraught with uncertainty. Learn to promptly and accurately diagnose patients with PF-ILD and apply contemporary evidence to treatment decisions.

  • Disclosure of Conflicts of Interest

    In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, CME/CE approval committee, and those in position to control the content of this activity disclose any relevant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

    All CME/CE educational activities sponsored by National Jewish Health are reviewed by our faculty CME/CE committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

    Kevin Brown, MD discloses grants from NHLBI and the Open Source Imaging Consoritum (OSIC), personal fees from Biogen, Galecto, Third Pole, Galapagos, Boehringer Ingelheim, Theravance, Lifemax, Pliant, Blade Therapeutics, Huitai Biomedicine, Lilly, Dispersol, DevPro Biopharma, and Humanetics outside the submitted work.

    Kevin Flaherty, MD discloses that he is a consultant for Bellerophon, Boehringer Ingelheim, Respivant, and Shionogi.

    Rebecca Keith, MD discloses that she is a speaker for Boehringer Ingelheim and Genentech.

    None of the following planners or reviewers have any relevant financial relationships to disclose: Amen Sergew, MD, Michael Mohning, MD, Andrea Harshman, MHA, CHCP, CMP-HC, Meghan Brenner, MA, Mandy Comeau, or the patient featured in the video segment.

  • Target Audience

    Pulmonologists, Radiologists, and Pathologists, as well as Primary Care Physicians, Registered Nurses, Nurse Practitioners, and Physician Assistants.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Define PF-ILD, identify conditions associated with PF-ILD, and describe the impact of PF-ILD on symptoms, pulmonary function, and mortality.
    2. Describe best practices for the early and accurate diagnosis of PF-ILD and the follow-up of patients with ILDs who are at risk for developing PF-ILD.
    3. Discuss evidence-based strategies and emerging therapies for the pharmacologic treatment of PF-ILD.
  • Accreditation and Credit Designation Statements

    National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    National Jewish Health designates this enduring material for 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Registered Nurses: 
    Provider approved by the California Board of Registered Nursing, Provider Number 12724 for 1.0 nursing contact hours.

  • Provider(s)/Educational Partner(s)

    Provided by National Jewish Health.

  • Commercial Support

    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

  • Tests/Evaluation

    To obtain credit, a score of 2 out of 3 or better on the post-test is required. There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

    1. Read the learning objectives and disclosures
    2. Study the educational activity
    3. Complete the post-test and the evaluation form

    If you successfully complete the post-test (score of 2 out of 3 or higher), your certificate will be made available immediately. If you have any questions relating to the accreditation of this activity, please contact: proed@njhealth.org.

  • Disclosure of Unlabeled Use

    The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

    No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

    Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

  • Disclaimer

    National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

    By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

    Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

  • Privacy Policy

    https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

    The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME/CE). 

    We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME/CE programming.

    If you decide to register for an Internet CME/CE program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME/CE activities.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Chronic Fibrosing ILD with a Progressive Lung Disease Phenotype (PF-ILD) occurs in multiple, overlapping clinical settings, and differentiating them can be frustrating and fraught with uncertainty. Learn to promptly and accurately diagnose patients with PF-ILD and apply contemporary evidence to treatment decisions.

  • Disclosure of Conflicts of Interest

    In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, CME/CE approval committee, and those in position to control the content of this activity disclose any relevant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

    All CME/CE educational activities sponsored by National Jewish Health are reviewed by our faculty CME/CE committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

    Kevin Brown, MD discloses grants from NHLBI and the Open Source Imaging Consoritum (OSIC), personal fees from Biogen, Galecto, Third Pole, Galapagos, Boehringer Ingelheim, Theravance, Lifemax, Pliant, Blade Therapeutics, Huitai Biomedicine, Lilly, Dispersol, DevPro Biopharma, and Humanetics outside the submitted work.

    Kevin Flaherty, MD discloses that he is a consultant for Bellerophon, Boehringer Ingelheim, Respivant, and Shionogi.

    Rebecca Keith, MD discloses that she is a speaker for Boehringer Ingelheim and Genentech.

    None of the following planners or reviewers have any relevant financial relationships to disclose: Amen Sergew, MD, Michael Mohning, MD, Andrea Harshman, MHA, CHCP, CMP-HC, Meghan Brenner, MA, Mandy Comeau, or the patient featured in the video segment.

  • Target Audience

    Pulmonologists, Radiologists, and Pathologists, as well as Primary Care Physicians, Registered Nurses, Nurse Practitioners, and Physician Assistants.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Define PF-ILD, identify conditions associated with PF-ILD, and describe the impact of PF-ILD on symptoms, pulmonary function, and mortality.
    2. Describe best practices for the early and accurate diagnosis of PF-ILD and the follow-up of patients with ILDs who are at risk for developing PF-ILD.
    3. Discuss evidence-based strategies and emerging therapies for the pharmacologic treatment of PF-ILD.
  • Accreditation and Credit Designation Statements

    National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    National Jewish Health designates this enduring material for 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Registered Nurses: 
    Provider approved by the California Board of Registered Nursing, Provider Number 12724 for 1.0 nursing contact hours.

  • Provider(s)/Educational Partner(s)

    Provided by National Jewish Health.

  • Commercial Support

    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

  • Tests/Evaluation

    To obtain credit, a score of 2 out of 3 or better on the post-test is required. There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

    1. Read the learning objectives and disclosures
    2. Study the educational activity
    3. Complete the post-test and the evaluation form

    If you successfully complete the post-test (score of 2 out of 3 or higher), your certificate will be made available immediately. If you have any questions relating to the accreditation of this activity, please contact: proed@njhealth.org.

  • Disclosure of Unlabeled Use

    The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

    No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

    Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

  • Disclaimer

    National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

    By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

    Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

  • Privacy Policy

    https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

    The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME/CE). 

    We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME/CE programming.

    If you decide to register for an Internet CME/CE program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME/CE activities.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/3/20